Merck sells eye business

Share this article:

First Merck sold its consumer business to Bayer. Now, it's also (almost) getting out of the eye-care business. The company announced Tuesday that it has sold part of the business to Santen Pharmaceutical.

The $600-million-plus-milestones deal includes rights to the eye products Cosop, Trusop and Timoptic in Japan and “key markets in Europe and Asia Pacific.” Merck said the sales for these products in these territories is around $400 million a year.

Merck will continue to sell these products in Latin America, Canada and Australia, but sold US rights to Akorn in 2013 and 2014.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters